374P - Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial

Background

Patient-reported outcomes (PROs) are a valuable component to understand treatment tolerability and toxicity. We have implemented an electronic system for monitoring PROs and quality of life (QOL) for patients enrolled in the I-SPY2 trial, a phase II trial evaluating the effect of novel neoadjuvant therapies for breast cancer. We associated patient demographic factors with symptoms, decline in physical function (PF), and tolerability to treatment.

Methods

Study population for this analysis includes 259 enrolled patients receiving combinations of experimental immunotherapy and chemotherapy. Patients completed PRO-CTCAE/PROMIS/FACT surveys reflecting symptom severity, symptom frequency, tolerability of drug, and physical function at baseline through follow up (12 months). CTCAE 5.0 was collected weekly at these timepoints to assess adverse events (AE). Odds ratio and regularized multi-variate regression was used to evaluate early symptoms predictive of a clinically significant decline in PF from baseline to post-treatment follow-up.

Results

Of 259 patients, 160 (58%) were White, 13 (5%) were Asian, 26 (10%) were African American (AA), and 25 (9.3%) were Hispanic. 25% of all patients had a clinically significant decline in PF between baseline and pre-surgery/follow-up. Symptom predictors of decline included high frequency of diarrhea and severity of joint pain. African American (AA) patients had higher severity of joint pain than White patients (OR = 14.9, P < 0.05). Within the first 12 weeks of treatment, AA patients and non-white (NW) patients were more likely to report severe vomiting than White patients (OR =13.22 and 12.72, P< 0.05 and P< 0.03 respectively). Overall, patients that reported lower tolerance to therapy had higher grade of AE. While patients with low-grade adverse events were less bothered by their side effects at follow-up, higher grade adverse events such as hypothyroidism impacted distress levels by more than double.

Conclusions

Among I-SPY2 participants, when higher grade of symptoms is persistent through follow up, it impacts physical function and tolerability even after end of therapy. Our study can allow physicians to be more diligent in active and post treatment monitoring.

Clinical trial identification

NCT01042379.

Editorial acknowledgement

Legal entity responsible for the study

I-SPY2 Trial Investigators.

Funding

Research reported in this manuscript was supported by the National Cancer Institute of the National Institutes of Health under award number P01CA210961. The authors wish to acknowledge the generous support of the study sponsors, Quantum Leap Healthcare Collaborative ( QLHC, 2013 to present) and the Foundation for the National Institutes of Health (2010 to 2012). The authors sincerely appreciate the ongoing support for the I-SPY2 Trial from the Safeway Foundation , the William K. Bowes, Jr. Foundation, Give Breast Cancer the Boot, QLHC and the Breast Cancer Research Foundation.

Disclosure

L. Esserman: Financial Interests, Institutional, Research Funding: Merck; Financial Interests, Personal, Advisory Board: Blue Cross Blue Shield; Financial Interests, Personal, Other, Website Author: UpToDate. All other authors have declared no conflicts of interest.